Monoclonal antibody

Pionyr Immunotherapeutics’ Phase 1a Study of TREM1-targeting Antibody PY159 for the Treatment of Solid Tumors Featured at ASCO 2023

Retrieved on: 
Thursday, May 25, 2023

A recommended dose of 3 mg/kg of PY159 has been determined, and seven expansion cohorts in prespecified indications are currently enrolling in the Phase 1b portion of the study.

Key Points: 
  • A recommended dose of 3 mg/kg of PY159 has been determined, and seven expansion cohorts in prespecified indications are currently enrolling in the Phase 1b portion of the study.
  • The study will be featured in a poster discussion session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6 in Chicago and virtually.
  • The poster titled, “A Phase 1a Dose Escalation Study of PY159, a Monoclonal Antibody Targeting TREM1, Triggering Receptor Expressed on Myeloid Cells 1,” will be featured in a poster discussion session at the ASCO 2023 Annual Meeting at 3-4:30 pm CDT on June 3, 2023.
  • The abstract is currently available on the ASCO 2023 website, and the poster will be available on the Pionyr company website here after the completion of the ASCO poster session.

Global Oncology R&D Activity Remains High and More Patients Have Been Treated for Cancer, says IQVIA Institute for Human Data Science

Retrieved on: 
Wednesday, May 24, 2023

Diversity and inclusion of Black/African American and Hispanic patient populations in oncology clinical trials lag behind trials in all other top therapeutic areas.

Key Points: 
  • Diversity and inclusion of Black/African American and Hispanic patient populations in oncology clinical trials lag behind trials in all other top therapeutic areas.
  • “Global oncology continues to discover, develop and deliver important novel treatments that benefit more patients,” says Murray Aitken, Executive Director, the IQVIA Institute for Human Data Science.
  • There is a growing interest for bispecific antibodies, including six compounds marketed globally for oncology and many in development for rare hematological cancers.
  • Cancer patient access: The global numbers of treated patients have increased annually at an average 5% over the past five years.

6th Annual Next-Gen Immuno-Oncology Conference: Focus on Combination Strategies, Pre-clinical and Translational Immune-oncology Developments (Boston, United States - June 22-23, 2023) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 23, 2023

The "6th Annual Next-Gen Immuno-Oncology Conference" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "6th Annual Next-Gen Immuno-Oncology Conference" has been added to ResearchAndMarkets.com's offering.
  • The 6th Annual Next Gen Immuno-Oncology Conference to be held on 22nd - 23rd June 2023, in Boston, would address the challenges and future directions in IO research.
  • This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development, and personalized immunotherapy.
  • Keynote presentations, Brainstorming Panel Discussions, and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

New Clarivate Biopharma Dealmaking Report Reveals Investment Patterns Set to Impact the Future of Medicine

Retrieved on: 
Wednesday, May 17, 2023

LONDON, May 17, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today released its new report, Biopharma Dealmaking in 2023.  This year's report examines how pharma companies are replenishing their pipelines as many face a steep patent cliff, with particular attention to such critical emerging modalities and technologies as antibody drug conjugates, artificial intelligence (AI) and machine learning, cell therapy, bispecific antibodies and RNA therapeutics.

Key Points: 
  • LONDON, May 17, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today released its new report, Biopharma Dealmaking in 2023 .
  • Instead, during 2022, the global biotech sector saw a drop off in its ability to raise finance, with investor enthusiasm waning.
  • A geographic analysis2 of dealmaking activity confirms that biotech innovation is greatly influenced by American companies, but that trend is declining.
  • The in-depth analysis of how pharma companies are replenishing their pipelines featured in the Biopharma Deals Report provides our customers with the answers they need to shape the future of healthcare."

New Clarivate Biopharma Dealmaking Report Reveals Investment Patterns Set to Impact the Future of Medicine

Retrieved on: 
Wednesday, May 17, 2023

LONDON, May 17, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today released its new report, Biopharma Dealmaking in 2023.  This year's report examines how pharma companies are replenishing their pipelines as many face a steep patent cliff, with particular attention to such critical emerging modalities and technologies as antibody drug conjugates, artificial intelligence (AI) and machine learning, cell therapy, bispecific antibodies and RNA therapeutics.

Key Points: 
  • LONDON, May 17, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today released its new report, Biopharma Dealmaking in 2023 .
  • Instead, during 2022, the global biotech sector saw a drop off in its ability to raise finance, with investor enthusiasm waning.
  • A geographic analysis2 of dealmaking activity confirms that biotech innovation is greatly influenced by American companies, but that trend is declining.
  • The in-depth analysis of how pharma companies are replenishing their pipelines featured in the Biopharma Deals Report provides our customers with the answers they need to shape the future of healthcare."

Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 16, 2023

The "Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • Insight On Bispecific Antibodies In Clinical Trials: > 700 Bispecific Antibodies
    Global Bispecific Antibodies Clinical Trials By Company, Indication and Phase
    The introduction of antibody-based therapeutics has been a game changer in the field of cancer therapy.
  • The continued expansion in research and development of antibody biologics has brought in the era of bispecific antibodies.
  • Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
    15.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

Retrieved on: 
Thursday, May 11, 2023

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2023.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2023.
  • The Collaboration and License Agreement with Akeso closed on January 17, 2023 after going effective following customary waiting periods.
  • In exchange for these rights, Summit committed to an upfront payment of $500 million, which was paid in two installments.
  • Operating cash outflow for the three month ended March 31, 2023 and 2022 was $13.1 million and $19.0 million, respectively.

Global Biopharmaceutical CMO & CRO Market is Expected to Reach $27.95 Billion by 2028: Players Include Toyobo, Samsung Biologics, Patheon, AbbVie and Binex - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 4, 2023

The abbreviations for contract research organisations and contract manufacturing companies in the pharmaceutical industry are biopharmaceutical CMO and CRO, respectively.

Key Points: 
  • The abbreviations for contract research organisations and contract manufacturing companies in the pharmaceutical industry are biopharmaceutical CMO and CRO, respectively.
  • Consumer demand for biopharmaceutical treatments has been a major driver of the biopharmaceutical industry's phenomenal growth.
  • Global Biopharmaceutical CMO and CRO Market is segmented based on the source, service, product, and region.
  • The biopharmaceutical CMO and CRO market is anticipated to grow quickly in the coming years as a result of these factors.

$15+ Billion Global Digital Biomanufacturing Market to 2035: Players Include GE Healthcare, Korber, Merck, Sartorius and Thermo Fisher Scientific

Retrieved on: 
Tuesday, May 2, 2023

Answer: The current global digital biomanufacturing market is anticipated to be worth around USD 15 billion.

Key Points: 
  • Answer: The current global digital biomanufacturing market is anticipated to be worth around USD 15 billion.
  • Question 6: Which segment, in terms of deployment options, accounts for the largest share in the global digital biomanufacturing market?
  • Question 8: What is the growth rate (CAGR) in the global digital biomanufacturing market?
  • Answer: The global digital biomanufacturing market size is projected to grow at a CAGR of ~11% in the coming years.

Global Digital Biomanufacturing Market 2023 - 2025: Increasing Number of Approved Biologics Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 27, 2023

Question 4: Which region has the highest market share in the global digital biomanufacturing market?

Key Points: 
  • Question 4: Which region has the highest market share in the global digital biomanufacturing market?
  • Question 6: Which segment, in terms of deployment options, accounts for the largest share in the global digital biomanufacturing market?
  • Question 8: What is the growth rate (CAGR) in the global digital biomanufacturing market?
  • Answer: The global digital biomanufacturing market size is projected to grow at a CAGR of ~11% in the coming years.